Abstracts tagged "anti-TNF therapy"

Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Claire I. Daien¹, Anne-Marie Dupuy Gorce², Edith Pinot², Thibault Mura³, Jean-Paul Cristol², Bernard Combe⁴ and Jacques Morel⁵, ¹Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Biochemistry, Hopital Lapeyronie, Montpellier, France, ³CIC, Hopital Gui De Chauliac, Montpellier, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…
Abstract Number: 2217 • 2012 ACR/ARHP Annual Meeting
Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients
Frank Behrens¹, Michaela Koehm¹, Diamant Thaci², Brigitte Krummel-Lorenz³, Gerd Greger⁴, Bianca Wittig⁴ and Harald Burkhardt⁵, ¹CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ²Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, ³CIRI/Endokrinologikum, Frankfurt/Main, Germany, ⁴Abbott GmbH & Co KG, Wiesbaden, Germany, ⁵CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany
Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…
Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting
The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…
Abstract Number: 826 • 2012 ACR/ARHP Annual Meeting
Predictors of Return to Work During 3 Years After Start of First Tumor Necrosis Factor Antagonist in a National Cohort of Biologics-Treated Patients with Rheumatoid Arthritis
Tor Olofsson¹, Ingemar F. Petersson², Jonas Eriksson³, Martin Englund², Pierre Geborek¹, Lennart T.H. Jacobsson⁴, Johan Askling⁵ and Martin Neovius³, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: To estimate predictors of return to work during 3 years following start of anti-TNF therapy in working-age RA patients with total work disability at…
Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Mathieu Verdet¹, Clément Guillou², Marie-Laure Potier², Martine Hiron², Fabienne Jouen³, Olivier Boyer⁴, Thierry Lequerré⁵ and Olivier Vittecoq⁶, ¹Rheumatology, Rouen University Hospital, Bois Guillaume, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Immunology, Rouen University Hospital, Rouen Cedex, France, ⁴Immunology, INSERM U905, University of Rouen, Rouen, France, ⁵Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum Berlin, Berlin, Germany, ⁴UCB Pharma, Braine, Belgium, ⁵UCSD School of Medicine, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…
Abstract Number: 828 • 2012 ACR/ARHP Annual Meeting
Association between Anti-Tumor Necrosis Factor Therapy and the Risk of Ischemic Stroke in Subjects with Rheumatoid Arthritis. Results From the British Society for Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA)
Audrey S. Low¹, Mark Lunt², Louise K. Mercer³, James B. Galloway⁴, Rebecca Davies⁵, Kath D. Watson¹, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium³, Deborah P. Symmons¹, William G. Dixon⁶, Kimme L. Hyrich⁵ and On behalf of the BSRBR⁷, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ⁶The University of Manchester, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) morbidity and mortality, with some studies suggesting an increased risk of stroke…
Abstract Number: 433 • 2012 ACR/ARHP Annual Meeting
Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries
Marieke J.H. Coenen¹, Masha Umicevic-Mirkov², Hans Scheffer², Sophine B. Krintel³, Sita H. Vermeulen⁴, Julia S. Johansen³, Wietske Kievit⁵, Mart A.F.J. van de Laar⁶, Piet L.C.M. van Riel⁵, Barbara Franke² and Merete L. Hetland⁷, ¹Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Human Genetics (855), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³DANBIO and Department of Rheumatology, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁴Human Genetics and Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Department of Rheumatology and DREAM registry, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) rate pain relief as the highest priority in treatment outcome, and tumor necrosis factor inhibitors (anti-TNF) have proven very…
Abstract Number: 2131 • 2012 ACR/ARHP Annual Meeting
An Evaluation of Prognostic Factors for Orthopaedic Joint Surgery in Rheumatoid Arthritis. Results From Two Multicentre UK Inception Cohorts (1986-2011)
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, David James⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young³, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, ⁴Rheumatology, Diana Princess of Wales Hospital, Grimsby, United Kingdom, ⁵Rheumatology Dept, St. Georges Hospital, London, United Kingdom, ⁶Academic Rheum/Clin Sci Bldg, City Hospital, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom
Background/Purpose: The need for orthopaedic surgery in Rheumatoid Arthritis (RA) is the result of failed medical treatment and a surrogate marker for joint destruction. Reliable…
Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting
Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Yair Molad¹ and Shachaf Ofer-Shiber², ¹Rheumatology Unit, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petach-Tikva, Israel, ²Internal Medicine H, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…
Abstract Number: 777 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study
Robert B. M. Landewé¹, Martin Rudwaleit², Désirée van der Heijde³, Maxime Dougados⁴, Walter P. Maksymowych⁵, Jürgen Braun⁶, Atul A. Deodhar⁷, Christian Stach⁸, Bengt Hoepken⁸, Geoffroy Coteur⁹, Danuta Kielar⁹, Andreas Fichtner⁸, Terri Arledge¹⁰ and Joachim Sieper¹¹, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Endokrinologikum Berlin, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Oregon Health & Science University, Portland, OR, ⁸UCB Pharma, Monheim am Rheim, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Rtp, NC, ¹¹Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Axial spondyloarthritis (axSpA ) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), as defined by the ASAS criteria.1 RAPID-axSpA (NCT01087762) is the first…
Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca⁵, ¹Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Clinic Hospital "Sf. Maria", Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 1341 • 2012 ACR/ARHP Annual Meeting
Beneficial Effect of Anti-TNF Therapy in the Lipoprotein Atherogenic Risk Profile in Comparison with DMARD Standard Therapy in RA Patients
Jaime Calvo-Alen¹, Ignacio Villa², Victor M. Martinez-Taboada³, Jose Luis Peña-Sagredo⁴, Mario Agudo⁴, Ana Carmen García⁵ and Juan Gomez-Gerique⁶, ¹Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ²Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Fundación 12 de Octubre, Madrid, Spain, ⁶Laboratorio de metabolismo lípidico y riesgo vascular, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: RA patients portend a greater risk of cardio-vascular complications than general population. Although most probably diverse mechanisms are implicated, quantity and quality changes in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].